-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
ImmunoPrecise Antibodies (CVE:IPA) Issues Earnings Results
ImmunoPrecise Antibodies (CVE:IPA) Issues Earnings Results
ImmunoPrecise Antibodies (CVE:IPA – Get Rating) released its quarterly earnings results on Wednesday. The company reported C($0.38) EPS for the quarter, reports. The firm had revenue of C$4.69 million for the quarter.
ImmunoPrecise Antibodies Stock Performance
IPA stock traded up C$0.37 during mid-day trading on Friday, reaching C$6.87. 14,074 shares of the stock traded hands, compared to its average volume of 20,186. The firm has a market capitalization of C$170.63 million and a PE ratio of -7.72. The business has a 50-day moving average of C$6.32 and a two-hundred day moving average of C$6.19. ImmunoPrecise Antibodies has a 52 week low of C$4.52 and a 52 week high of C$8.99. The company has a quick ratio of 3.60, a current ratio of 4.05 and a debt-to-equity ratio of 3.38.
Get ImmunoPrecise Antibodies alerts:About ImmunoPrecise Antibodies
(Get Rating)
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes.Featured Stories
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
- MarketBeat: Week in Review 9/12 – 9/16
- No One Told These 3 Stocks It's a Down Week
- Is There a Cure for What is Ailing Teladoc Stock?
Receive News & Ratings for ImmunoPrecise Antibodies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoPrecise Antibodies and related companies with MarketBeat.com's FREE daily email newsletter.
ImmunoPrecise Antibodies (CVE:IPA – Get Rating) released its quarterly earnings results on Wednesday. The company reported C($0.38) EPS for the quarter, reports. The firm had revenue of C$4.69 million for the quarter.
免疫精抗体公司(CVE：IPA-GET Rating)周三发布了季度收益报告。据报道，该公司公布本季度每股收益为0.38加元。该公司本季度的收入为469万加元。
ImmunoPrecise Antibodies Stock Performance
免疫精确化抗体库存表现
IPA stock traded up C$0.37 during mid-day trading on Friday, reaching C$6.87. 14,074 shares of the stock traded hands, compared to its average volume of 20,186. The firm has a market capitalization of C$170.63 million and a PE ratio of -7.72. The business has a 50-day moving average of C$6.32 and a two-hundred day moving average of C$6.19. ImmunoPrecise Antibodies has a 52 week low of C$4.52 and a 52 week high of C$8.99. The company has a quick ratio of 3.60, a current ratio of 4.05 and a debt-to-equity ratio of 3.38.
IPA股价在周五午盘交易中上涨0.37加元，达到6.87加元。该股有14,074股易手，而其平均成交量为20,186股。该公司市值为1.7063亿加元，市盈率为-7.72。该业务的50日移动均线切入位在6.32加元，200日移动均线切入位在6.19加元。免疫精抗体的52周低点为4.52加元，52周高位为8.99加元。该公司的速动比率为3.60，流动比率为4.05，债务权益比为3.38。
About ImmunoPrecise Antibodies
关于免疫精确化抗体
(Get Rating)
(获取评级)
Featured Stories
专题报道
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
- MarketBeat: Week in Review 9/12 – 9/16
- No One Told These 3 Stocks It's a Down Week
- Is There a Cure for What is Ailing Teladoc Stock?
- 股市：红海中的三座强国
- 第四季度值得考虑的3家银行
- MarketBeat：回顾一周9/12-9/16
- 没有人告诉这三只股票这是下跌的一周
- 有什么办法可以治愈Teladoc股票的问题吗？
Receive News & Ratings for ImmunoPrecise Antibodies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoPrecise Antibodies and related companies with MarketBeat.com's FREE daily email newsletter.
每天收到关于免疫精准抗体的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯，接收最新新闻和分析师对免疫精准抗体和相关公司的评级的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧